US Pharma and Biotech Summit
The US Pharma and Biotech Summit returns to New York on May 11, 2022. Industry leaders and FT journalists will discuss regional and global trends in areas such as drug discovery, clinical development and market access. How is American investment in life sciences evolving? What are the prospects for healthcare reform? How can pharma companies become more patient-centric? Join us in-person and online to learn from experts, engage with leaders and network with peers.
Themes
Driving investment
How is the American life sciences investment landscape evolving? What shifts are we seeing in M&A activity? How do investors decide where to put their money?
Accelerating innovation
What is the true potential of AI to transform R&D? To what extent is cross-industry innovation and collaboration sustainable beyond the pandemic? How can pharma workforces become more productive?
Enhancing access
How can pharma companies become more patient-centric? How could proposed US healthcare reforms affect the industry? How can cell and gene therapies be made more affordable and accessible?
Why Attend?
Understand
how pharma’s role in American healthcare is evolving through innovation in R&D, drug delivery and patient access
Discover
new approaches to drug development with the potential to transform pipelines and bring products to market faster
Connect
with some of the biggest names in the industry to learn about the latest trends, exchange ideas and build relationships
Covid-19 safety
The health and safety of our guests, partners and staff remains our top priority. We will continue to monitor and follow Government guidelines throughout the planning, opening and running of the US Pharma and Biotech Summit. View our Covid-19 Plan for more information.
"An incredibly well-curated event. Agreat combination of thought-provoking discussions and networking."
Speaking Opportunities
Ciaran Larkin
ciaran.larkin@ft.com
Delegate Services
Sean Hammond
sean.hammond@ft.com
Not a subscriber of the FT?
When you purchase a ticket to one of our events you will receive a trial subscription for £1 giving you full digital access to essential news and opinion.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice